What triggered the legal action?

Allegations relating to statements about development progress, supply chain strength and operational partnerships.

Who lodged the filings?

Multiple US firms representing holders of Telix’s Nasdaq-listed securities.

Has Telix commented publicly?

The article summarises the legal filings; any updates from the company would typically be issued to the market through official channels.

ASX 200 Update: Telix Pharmaceuticals (ASX:TLX) Drops as US Class Actions Mount

2 min read | November 14, 2025 01:56 PM AEDT | By Sam

Google News:

ASX 200 Update: Telix Pharmaceuticals (ASX:TLX) Drops as US Class Actions Mount — Image source: Shutterstock

Recent News

AI Infrastructure Trends Across ASX 100 Technology Leaders

Which ASX Software Stocks Are Turning the AI Wave Into Actual Revenue?

Why ASX 200 Oil and Gas Stay in Focus

Caught in the Tug-of-War: Investing in Oil and Gas During the Energy T...

Make Kalkine Media
My Trusted Source

Highlights

Telix Pharmaceuticals faces multiple US class actions linked to disclosures about development programs.

Legal filings target statements relating to prostate cancer therapeutics and supply chain strength.

TLX shares weaken during a risk-off trading session as the asx200 trends lower.

Telix Pharmaceuticals shares weakened after multiple US class actions alleged overstated progress on prostate cancer candidates and supply chain strength. The filings added pressure to a market already trading with softer sentiment.

Legal Challenges Hit Telix Pharmaceuticals

Telix Pharmaceuticals Ltd (ASX:TLX) traded lower in the morning session after confirmation that several US law firms have initiated class actions against the company. The filings relate to Telix’s Nasdaq-listed American Depositary Shares and centre on disclosures covering development progress, supply chain capability and commercial partnerships.

Multiple firms — including Berger Montague, Pomerantz, Glancy Prongay & Murray, DiCello Levitt, The Law Offices of Howard G Smith and Rosen Law Firm — have lodged separate actions on behalf of investors who acquired the company’s US-listed securities earlier this year.

What the Filings Claim

According to the statements released by the firms, the actions allege that Telix overstated the advancement of its prostate cancer therapeutic programs and portrayed its operational relationships in a stronger position than they were. The filings also reference disclosures that came under regulatory review, including a subpoena issued by the US Securities and Exchange Commission requesting documents tied to the development program.

The complaints assert that these disclosures created an inaccurate picture of the company’s operating outlook and that subsequent market reactions resulted in losses for holders of the company’s US-listed securities.

Market Reaction

Trading in the company’s US securities reflected weaker sentiment following updates from the legal groups. Local trading mirrored that tone, with TLX easing as broader risk conditions pressured healthcare, biotechnology and growth-exposed names.

The session coincided with declines across Wall Street and local markets as the asx200 opened softer, weighed down by global volatility and caution across defensive and growth sectors alike.

Frequently Asked Questions

What triggered the legal action?

Allegations relating to statements about development progress, supply chain strength and operational partnerships.
Who lodged the filings?

Multiple US firms representing holders of Telix’s Nasdaq-listed securities.
Has Telix commented publicly?

The article summarises the legal filings; any updates from the company would typically be issued to the market through official channels.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.